Evidence map›Paper›PMID 35409062›Full record

ArticleInternational journal of molecular sciences2022

A Comparison of Network-Based Methods for Drug Repurposing along with an Application to Human Complex Diseases.

Giulia Fiscon, Federica Conte, Lorenzo Farina, Paola Paci

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Network Medicine-Based Repurposing of Mesalazine for Atherosclerosis Treatment.Journal of cardiovascular translational research · 2025
    Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Network Medicine: A Potential Approach for Virtual Drug Screening.Pharmaceuticals (Basel, Switzerland) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Giulia FisconDepartment of Computer, Control and Management Engineering "Antonio Ruberti" (DIAG), Sapienza University of Rome, Via Ariosto 25, 00185 Rome, Italy.ORCID 0000-0002-3354-8203
Federica ConteInstitute for Systems Analysis and Computer Science "Antonio Ruberti", National Research Council, Via dei Taurini 19, 00185 Rome, Italy.ORCID 0000-0003-0427-1476
Lorenzo FarinaDepartment of Computer, Control and Management Engineering "Antonio Ruberti" (DIAG), Sapienza University of Rome, Via Ariosto 25, 00185 Rome, Italy.ORCID 0000-0001-8314-6029
Paola PaciDepartment of Computer, Control and Management Engineering "Antonio Ruberti" (DIAG), Sapienza University of Rome, Via Ariosto 25, 00185 Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug repurposing strategy, proposing a therapeutic switching of already approved drugs with known medical indications to new therapeutic purposes, has been considered as an efficient approach to unveil novel drug candidates with new pharmacological activities, significantly reducing the cost and shortening the time of de novo drug discovery. Meaningful computational approaches for drug repurposing exploit the principles of the emerging field of Network Medicine, according to which human diseases can be interpreted as local perturbations of the human interactome network, where the molecular determinants of each disease (disease genes) are not randomly scattered, but co-localized in highly interconnected subnetworks (disease modules), whose perturbation is linked to the pathophenotype manifestation. By interpreting drug effects as local perturbations of the interactome, for a drug to be on-target effective against a specific disease or to cause off-target adverse effects, its targets should be in the nearby of disease-associated genes. Here, we used the network-based proximity measure to compute the distance between the drug module and the disease module in the human interactome by exploiting five different metrics (minimum, maximum, mean, median, mode), with the aim to compare different frameworks for highlighting putative repurposable drugs to treat complex human diseases, including malignant breast and prostate neoplasms, schizophrenia, and liver cirrhosis. Whilst the standard metric (that is the minimum) for the network-based proximity remained a valid tool for efficiently screening off-label drugs, we observed that the other implemented metrics specifically predicted further interesting drug candidates worthy of investigation for yielding a potentially significant clinical benefit.

Indexed as

Computational BiologyDrug RepositioningDrug DiscoveryHumansdrug repurposingnetwork medicinenetwork theory

Identifiers

PMID35409062
PMCPMC8999012

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.